AZ starts work on record-setting plant in China

AstraZeneca ($AZN) began construction this week of the corporate-record-setting manufacturing plant in China Medical City, Jiangsu Province, that it announced in October. The company said at the time that the $230 million financial commitment is its largest for a single manufacturing facility.

AZ expects to produce IV and solid dosage form treatments at the new facility. It will produce both its own branded drugs and branded generics, reports Shanghai Daily.

The plant, expected to be completed in late 2013, adds to AZ's manufacturing portfolio in China, according to the report.  Its manufacturing and supply site in Wuxi New District, Jiangsu Province, has been operating since 2001.

The manufacturing capacity for generics aligns with AZ's acquisition in November of privately held generics maker Guangdong Beikang Pharmaceutical.

- see the story

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.